Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,100
datasets available to search
ShareScore release 0.9.0
Dataset results
2,100 results for “nodes”
Lymph node metastasis evolution drives cancer immune evasion and drug resistance
GEO Series GSE93583. Homo sapiens. 39 samples. Type: Genome variation profiling by SNP array.
microRNA expression profile related to lymph node status in women with stage grade 1-2-3 endometrial cancer
GEO Series GSE75968. Homo sapiens; synthetic construct. 24 samples. Type: Non-coding RNA profiling by array.
Dataset related to article "Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?"
<p>OBJECTIVE:</p> <p>To evaluate safety and efficacy of image guided-hypofractionated radiation therapy (IG-HRT) in patients with thoracic nodes oligometastases.</p> <p>METHODS:</p> <p>The present study is a multicenter analysis. Oligometastatic patients, affected by a maximum of five active lesions in three or less different organs, treated with IG-HRT to thoracic nodes metastases between 2012 and 2017 were included in the analysis. Primary end point was local control (LC), secondary end points were overall survival (OS), progression-free survival, acute and late toxicity. Univariate and multivariate analysis were performed to identify possible prognostic factors for the survival end points.</p> <p>RESULTS:</p> <p>76 patients were included in the analysis. Different RT dose and fractionation schedules were prescribed according to site, number, size of the lymph node(s) and to respect dose constraints for relevant organs at risk. Median biologically effective dose delivered was 75 Gy (interquartile range: 59-86 Gy). Treatment was optimal; one G1 acute toxicity and seven G1 late toxicities of any grade were recorded. Median follow-up time was 23.16 months. 16 patients (21.05%) had a local progression, while 52 patients progressed in distant sites (68.42 %).Median local relapse free survival was not reached, LC at 6, 12 and 24 months was 96.05% [confidence interval (CI) 88.26<em>-</em>98.71%], 86.68% (CI 75.86<em>-</em>92.87) and 68.21% (CI 51.89<em>-</em>80.00%), respectively. Median OS was 28.3 months (interquartile range 16.1<em>-</em>47.2). Median progression-freesurvival was 9.2 months (interquartile range 4.1<em>-</em>17.93).At multivariate analysis, RT dose, colorectal histology, systemic therapies were correlated with LC. Performance status and the presence of metastatic sites other than the thoracic nodes were correlated with OS. Local response was a predictor of OS.</p> <p>CONCLUSION:</p> <p>IG-HRT for thoracic nodes was safe and feasible. Higher RT doses were correlated to better LC and should be taken in consideration at least in patients with isolated nodal metastases and colorectal histology.</p> <p>ADVANCES IN KNOWLEDGE:</p> <p>Radiotherapy is safe and effective treatment for thoracic nodes metastases, higher radiotherapy doses are correlated to better LC. Oligometastatic patients can receive IG-HRT also for thoracic nodes metastases.</p>
Dataset related to article "The Number of Metastatic Lymph Nodes is a Useful Predictive Factor for Recurrence after Surgery for Nonmetastatic Nonfunctional Neuroendocrine Neoplasm of the Pancreas."
<p>Nodal involvement (actually categorized as positive or negative) is an important prognostic factor after surgery for pancreatic neuroendocrine neoplasms (pNENs). We aim to evaluate the predictive role of the number of nodal metastases after pancreatic resection for pNENs. We analyzed from a prospectively maintained database all pancreatic resections for nonmetastatic nonfunctioning pNENs performed in our institution from 2011 to 2016. According to the number of nodal metastases, enhancing the actual categorization, we distinguished the following: N0, no nodal metastases; N1, 1-3 metastatic lymph nodes; and N2, metastases in 4 or more regional lymph nodes. Recurrence and disease-free survival (DFS) were evaluated. The predictive value in terms of recurrence for each clinicopathological data, including the number of metastatic lymph nodes, was calculated. Univariate and multivariate analyses were conducted. 77 patients underwent pancreatic surgery for pNENs. N0, N1, and N2 resections were found in 52 (67.5%), 16 (20.8%), and 9 (11.7%) cases, respectively. Mean follow-up of the entire cohort was 48 (±25) months. The recurrence rate was 11.8%, and the mean time of recurrence was 12 (±14) months. DFS was 83.7 months (76.0 - 91.5). At a univariate analysis, factors associated with recurrence were mitotic count (OR 1.19, <em>p</em> = 0.001), Ki67 value (OR 1.06, <em>p</em> = 0.001), the presence of nodal metastases (OR 11.54, <em>p</em> = 0.002), and metastases in 4 or more regional lymph nodes (N2) (OR 30.19, <em>p</em> = 0.002). At a multivariate analysis, only mitotic count (OR 1.51, <em>p</em> = 0.005) and N2 resection (OR 134.74, <em>p</em> = 0.002) were found to be predictive factors of recurrence. The number of metastatic lymph nodes and mitotic count is the most significant predictive factors of recurrence after pancreatic surgery for nonmetastatic nonfunctioning pNENs.</p>
Dataset related to article "Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer"
<p><strong> Abstract</strong></p><p>Background: Prediction of survival and radiation therapy response is challenging in head and neck cancer with metastatic lymph nodes (LNs). Here we developed novel radiomics- and clinical-based predictive models.</p><p>Methods: Volumes of interest of LNs were employed for radiomic features extraction. Radiomic and clinical features were investigated for their predictive value relatively to locoregional failure (LRF), progression-free survival (PFS), and overall survival (OS) and used to build multivariate models.</p><p>Results: Hundred and six subjects were suitable for final analysis. Univariate analysis identified two radiomic features significantly predictive for LRF, and five radiomic features plus two clinical features significantly predictive for both PFS and OS. The area under the curve of receiver operating characteristic curve combining clinical and radiomic predictors for PFS and OS resulted 0.71 (95%CI: 0.60-0.83) and 0.77 (95%CI: 0.64-0.89).</p><p>Conclusions: Radiomic and clinical features resulted to be independent predictive factors, but external independent validation is mandatory to support these findin</p>
Dataset related to article "Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Neo-Adjuvant Chemotherapy: Clinical Experience with Node-Negative and Node-Positive Disease Prior to Systemic Therapy"
<p>This record contains raw data related to article "Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Neo-Adjuvant Chemotherapy: Clinical Experience with Node-Negative and Node-Positive Disease Prior to Systemic Therapy"</p><p>Abstract</p><p><strong>Background: </strong>Sentinel lymph node biopsy (SLNB) has emerged as the standard procedure to replace axillary lymph node dissection (ALND) in breast cancer (BC) patients undergoing neo-adjuvant chemotherapy (NAC). SLNB is accepted in clinically node-negative (cN0) patients; however, its role in clinically node-positive (cN+) patients is debatable.</p><p><strong>Methods: </strong>We performed a retrospective analysis of BC patients undergoing NAC and SLNB. Our aim was to evaluate the clinical significance of SLNB in the setting of NAC. This was accomplished by comparing the characteristics and oncological outcomes between cN0 and cN+ patients prior to NAC and type of axillary surgery.</p><p><strong>Results: </strong>A total of 291 patients were included in the analysis: 131 were cN0 and 160 were cN+ who became ycN0 after NAC. At a median follow-up of 43 months, axillary recurrence occurred in three cN0 (2.3%) and two cN+ (1.3%) patients. However, there were no statistically significant differences in oncological outcomes (disease-free survival, distant disease-free survival, overall survival, and breast-cancer-specific survival) between cN0 and cN+ patients nor between patients treated with SLNB only or ALND.</p><p><strong>Conclusions: </strong>SLNB in the setting of NAC is an acceptable procedure with a general good prognosis and low axillary failure rates for both cN0 and cN+ patients.</p>
Summary statistics for node removal
Open the record for dataset details and reuse information.
Dataset related to article "Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer"
<p>This record contains raw data related to article “Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer"</p> <p>Because the risk of relapse of node-negative breast cancer (BC) is largely varying, we evaluated the prognosis of a cohort of 1276 patients with this disease and the factors associated with increased risk of relapse. Overall, in nodenegative BC, age, hormonal receptor status, tumor size, and Ki67 were prognostic factors. The triple-negative BC subtype was not associated with a poorer prognosis compared with the human epidermal growth factor receptor 2-positive subtype, but showed a worse overall survival compared with luminal-like BC. Background: Because the risk of relapse of node-negative breast cancer (BC) is varying, we evaluated the prognosis of patients with this disease and the factors associated with increased risk of relapse. Patients and Methods: The clinical charts of patients with BC with evidence of negative nodes and with a potential 5-year follow-up were retrospectively reviewed</p>
Sino atrial node beating rate
Open the record for dataset details and reuse information.
Dataset related to article "CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression"
<p>This record contains raw data related to article "CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression"</p> <p>Luminal B breast cancers (BC) have a more aggressive behavior associated with a higher rate of tumor relapse and worse prognosis compared to luminal A tumors. In this study, we evaluated the involvement of specific epithelial-to-mesenchymal transition- (EMT-) and immune-related pathways in the dissemination of luminal B BC cells. The expression of 42 EMT- and immune-related genes was evaluated in matched sentinel lymph nodes (SLNs) analyzed by the one-step nucleic acid amplification assay (OSNA) and primary tumors of 40 luminal B BC patients by gene array and immunohistochemistry. The results were validated in an independent group of 150 luminal B tumors by immunohistochemistry and immunofluorescence and using gene expression data from 315 luminal B BC patients included in the Metabric dataset. We found that the expression of <em>CXCR4</em> (<em>p</em> = 3.28<em>E</em> - 02) and <em>CD163</em> (<em>p</em> = 6.92<em>E</em> - 03) was significantly upregulated in SLNs of recurrent luminal B BC patients. Luminal B primary tumors overexpressing CXCR4 were characterized by an increased expression of vimentin and a high content of CD163-positive macrophages. Bioinformatics analysis confirmed the correlation of <em>CXCR4</em> with <em>CXCL12</em>, <em>VIM</em>, and <em>CD163</em> expression and LN involvement. Our results suggest that the upregulation of the CXCR4/CXCL12 pathway and the presence of protumor macrophages in the primary tumor and SLNs sustain the aggressiveness of an important subgroup of luminal B BC.</p>
Dataset related to article "Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial "
<p>This record contains raw data related to article “Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial"</p> <p>Abstract</p> <p><strong>Background: </strong> The SINODAR-ONE trial is a prospective noninferiority multicenter randomized study aimed at assessing the role of axillary lymph node dissection (ALND) in patients undergoing either breast-conserving surgery or mastectomy for T1-2 breast cancer (BC) and presenting one or two macrometastatic sentinel lymph nodes (SLNs). The endpoints were to evaluate whether SLN biopsy (SLNB) only was associated with worsening of the prognosis compared with ALND in terms of overall survival (OS) and relapse.</p> <p><strong>Methods: </strong> Patients were randomly assigned (1:1 ratio) to either removal of ≥ 10 axillary level I/II non-SLNs followed by adjuvant therapy (standard arm) or no further axillary treatment (experimental arm).</p> <p><strong>Results: </strong> The trial started in April 2015 and ceased in April 2020, involving 889 patients. Median follow-up was 34.0 months. There were eight deaths (ALND, 4; SNLB only, 4), with 5-year cumulative mortality of 5.8% and 2.1% in the standard and experimental arm, respectively (p = 0.984). There were 26 recurrences (ALND 11; SNLB only, 15), with 5-year cumulative incidence of recurrence of 6.9% and 3.3% in the standard and experimental arm, respectively (p = 0.444). Only one axillary lymph node recurrence was observed in each arm. The 5-year OS rates were 98.9% and 98.8%, in the ALND and SNLB-only arm, respectively (p = 0.936).</p> <p><strong>Conclusions: </strong> The 3-year survival and relapse rates of T1-2 BC patients with one or two macrometastatic SLNs treated with SLNB only, and adjuvant therapy, were not inferior to those of patients treated with ALND. These results do not support the use of routine ALND.</p>
Laparoscopic Sentinel Lymph Node Sampling
<p>Stepwise Laparoscopic Sentinel Node Sampling </p> <p>Full video available on: www.gnyaefellow.com</p> <p> </p>
Discordant molecular subtype classification of muscle-invasive bladder cancer and matched lymph-node metastases occurs preferentially in the Basal/Squamous-like subtype.
GEO Series GSE101723. Homo sapiens. 28 samples. Type: Expression profiling by array.
TCRseq of Rpl18*-specific T cells from MC38 tumor and draining lymph node
GEO Series GSE302185. Mus musculus. 12 samples. Type: Other.
Genome-wide copy number analysis for occult lymph node metastasis in oral squamous cell carcinoma
GEO Series GSE31984. Homo sapiens. 60 samples. Type: SNP genotyping by SNP array; Genome variation profiling by SNP array.
Lack of genetic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases
GEO Series GSE38888. Homo sapiens. 42 samples. Type: Genome variation profiling by genome tiling array.
Gene expression profiles of mouse sentinel lymph nodes (SLNs) in xenotransplanted and non tumor bearing CB17 SCID.
GEO Series GSE30688. Mus musculus. 9 samples. Type: Expression profiling by array.
Transcriptomic profiling of tumor-infiltrating and lymph node-derived Treg and B cells in Foxp3-Cre-YFP and Foxp3-Cre-YFP Appl2f/f melanoma-bearing Mice
GEO Series GSE294977. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment "
<p>This record contains raw data related to article "Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment"</p><p>Abstract</p><p><strong>Background: </strong>The initial results of the SINODAR-ONE randomized clinical trial reported that patients with T1-2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with breast-conserving surgery, sentinel lymph node biopsy only, and adjuvant therapy did not present worse 3-year survival, regional recurrence, or distant recurrence rates compared with those treated with axillary lymph node dissection. To extend the recommendation of axillary lymph node dissection omission even in patients treated with mastectomy, a sub-analysis of the SINODAR-ONE trial is presented here.</p><p><strong>Methods: </strong>Patients with T1-2 breast cancer and no more than two metastatic sentinel lymph nodes undergoing mastectomy were analysed. After sentinel lymph node biopsy, patients were randomly assigned to receive either axillary lymph node dissection followed by adjuvant treatment (standard arm) or adjuvant treatment alone (experimental arm). The primary endpoint was overall survival. The secondary endpoint was recurrence-free survival.</p><p><strong>Results: </strong>A total of 218 patients were treated with mastectomy; 111 were randomly assigned to the axillary lymph node dissection group and 107 to the sentinel lymph node biopsy-only group. At a median follow-up of 33.0 months, there were three deaths (two deaths in the axillary lymph node dissection group and one death in the sentinel lymph node biopsy-only group). There were five recurrences in each treatment arm. No axillary lymph node recurrence was observed. The 5-year overall survival rates were 97.8 and 98.7 per cent in the axillary lymph node dissection treatment arm and the sentinel lymph node biopsy-only treatment arm, respectively (P = 0.597). The 5-year recurrence-free survival rates were 95.7 and 94.1 per cent in the axillary lymph node dissection treatment arm and the sentinel lymph node biopsy treatment arm, respectively (P = 0.821).</p><p><strong>Conclusion: </strong>In patients with T1-2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with mastectomy, the overall survival and recurrence-free survival rates of patients treated with sentinel lymph node biopsy only were not inferior to those treated with axillary lymph node dissection. To strengthen the conclusion of the trial, the enrolment of patients treated with mastectomy was reopened as a single-arm experimental study.</p><p> </p>
Sentinel lymph node biopsy in uterine carcinoma
<p>Rationale for implementation and tips & tricks for successful mapping</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.